Skip to main content

Table 1 Pharmacokinetics of TRU-015

From: Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis

Group (mg/kg) Area under the curve from time 0 to infinity (μg/h/ml) Maximum concentration of drug (μg/ml) Half-life (hours) Coefficient of variability (%)
0.5 1,342 13.8 281 59.1
1.5 7,082 58.2 282 26.5
5 18,140 154 295 33.4
15 71,753 462 409 32.8